Verici Dx plc (VRCDF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Verici Dx plc (VRCDF) with AI Score 61/100 (Hold). Verici Dx plc is an immuno-diagnostics company focused on the kidney transplantation market. They are developing a suite of tests to improve outcomes for transplant patients. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Verici Dx plc (VRCDF) Healthcare & Pipeline Overview
Verici Dx plc is a UK-based immuno-diagnostics company specializing in pre- and post-transplant tests for the kidney transplantation market. Their focus on early rejection and long-term graft failure prediction differentiates them within the diagnostics sector, addressing a critical need for improved patient outcomes and reduced healthcare costs.
Investment Thesis
Verici Dx presents a focused investment opportunity within the immuno-diagnostics space, specifically targeting the kidney transplantation market. The company's pipeline of diagnostic tests, including Clarava, Tuteva, and Protega, addresses critical unmet needs in predicting and managing transplant rejection and graft failure. With a gross margin of 105.8%, the company demonstrates potential for profitability as its products reach commercialization. Key value drivers include successful completion of clinical trials, regulatory approvals, and strategic partnerships for market access. The company's relatively small size and focused product pipeline also present potential risks, including dependence on successful product development and regulatory hurdles.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 105.8% indicates strong potential profitability upon commercialization of diagnostic tests.
- Focus on the kidney transplantation market addresses a significant unmet need for improved diagnostic and prognostic tools.
- Pipeline includes Clarava, Tuteva, and Protega, covering pre- and post-transplant monitoring for rejection and graft failure.
- Incorporated in 2020, indicating a relatively young company with potential for rapid growth.
- Market capitalization of $0.00B suggests the company is in the early stages of development and commercialization.
Competitors & Peers
Strengths
- Focus on the specific niche of kidney transplantation diagnostics.
- Proprietary diagnostic tests and technologies.
- Potential for high gross margins.
- Experienced management team with expertise in immuno-diagnostics.
Weaknesses
- Limited operating history as a relatively new company.
- Dependence on successful product development and regulatory approvals.
- Small market capitalization and limited financial resources.
- Concentration of product pipeline on kidney transplantation.
Catalysts
- Completion of clinical trials for Clarava, Tuteva, and Protega.
- Regulatory approvals for diagnostic tests in key markets.
- Strategic partnerships with pharmaceutical companies and healthcare providers.
- Expansion of product portfolio to address other aspects of kidney disease.
- Leveraging data analytics for personalized medicine approaches.
Risks
- Competition from larger diagnostic companies.
- Regulatory hurdles and delays in obtaining approvals.
- Changes in reimbursement policies.
- Technological advancements that could render its products obsolete.
- Dependence on successful product development and commercialization.
Growth Opportunities
- Expansion of Product Portfolio: Verici Dx has the opportunity to expand its product portfolio beyond its current pipeline of Clarava, Tuteva, and Protega. By developing new diagnostic tests for other aspects of kidney transplantation or related conditions, the company can increase its revenue streams and market share. The timeline for this growth opportunity is ongoing, as the company continues to invest in research and development. The market size for related diagnostics is estimated to be substantial, given the increasing prevalence of kidney disease and transplantation.
- Strategic Partnerships and Collaborations: Verici Dx can pursue strategic partnerships and collaborations with pharmaceutical companies, transplant centers, and other healthcare providers to accelerate the adoption of its diagnostic tests. These partnerships can provide access to new markets, funding, and expertise. The timeline for securing such partnerships is within the next 1-3 years. The potential market reach through partnerships is significant, as it can expand the company's presence beyond its current geographic focus.
- Geographic Expansion: Verici Dx can expand its geographic reach beyond the United Kingdom and Europe. By entering new markets, such as the United States and Asia, the company can tap into a larger pool of potential customers. The timeline for geographic expansion is within the next 3-5 years. The market size in these regions is substantial, given the high prevalence of kidney disease and transplantation rates.
- Regulatory Approvals and Reimbursement: Obtaining regulatory approvals and securing favorable reimbursement policies for its diagnostic tests are critical growth opportunities for Verici Dx. These approvals and policies can facilitate the adoption of its tests by healthcare providers and ensure that they are covered by insurance. The timeline for achieving these milestones is dependent on the regulatory processes in each market. Successful regulatory approvals and reimbursement can significantly increase the market access and revenue potential for Verici Dx.
- Personalized Medicine and Data Analytics: Verici Dx can leverage its diagnostic data to develop personalized medicine approaches for kidney transplant patients. By analyzing patient data and identifying biomarkers that predict transplant outcomes, the company can help clinicians tailor treatment strategies to individual patients. The timeline for this growth opportunity is ongoing, as the company continues to collect and analyze patient data. The market size for personalized medicine is growing rapidly, driven by advancements in genomics and data analytics.
Opportunities
- Expansion of product portfolio to address other aspects of kidney disease.
- Strategic partnerships with pharmaceutical companies and healthcare providers.
- Geographic expansion into new markets.
- Leveraging data analytics for personalized medicine approaches.
Threats
- Competition from larger diagnostic companies.
- Regulatory hurdles and delays in obtaining approvals.
- Changes in reimbursement policies.
- Technological advancements that could render its products obsolete.
Competitive Advantages
- Proprietary diagnostic tests and technologies.
- Focus on the specific niche of kidney transplantation.
- Strong relationships with transplant centers and key opinion leaders.
- Data analytics capabilities for personalized medicine.
About VRCDF
Verici Dx plc, incorporated in 2020 and based in Penarth, United Kingdom, is an immuno-diagnostics company focused on transforming kidney transplant outcomes. Recognizing the significant challenges in managing kidney transplant patients, Verici Dx is developing a suite of diagnostic tests designed to provide clinicians with actionable information at critical stages of the transplantation process. Their initial focus is on addressing the unmet needs in predicting early acute rejection, monitoring for acute cellular rejection, and forecasting the risk of fibrosis and long-term graft failure. The company's in-development product pipeline includes Clarava, a pre-transplant prognosis test designed to assess the risk of early acute rejection; Tuteva, a post-transplant test focused on detecting acute cellular rejection; and Protega, a liquid biopsy test aimed at predicting the risk of fibrosis and long-term graft failure. These tests leverage advanced immuno-diagnostics techniques to provide clinicians with a more comprehensive understanding of a patient's transplant status, enabling more personalized and effective treatment strategies. By focusing on the kidney transplantation market, Verici Dx aims to improve patient outcomes, reduce healthcare costs, and enhance the overall quality of life for transplant recipients.
What They Do
- Develops pre-transplant prognostic tests to assess the risk of early acute rejection in kidney transplant patients.
- Creates post-transplant tests focused on detecting acute cellular rejection.
- Develops liquid biopsy tests to predict the risk of fibrosis and long-term graft failure.
- Offers diagnostic solutions for the kidney transplantation market.
- Aims to improve patient outcomes and reduce healthcare costs associated with kidney transplantation.
- Utilizes immuno-diagnostics techniques to provide clinicians with actionable information.
- Focuses on personalized medicine approaches for kidney transplant patients.
Business Model
- Develops and commercializes diagnostic tests for the kidney transplantation market.
- Generates revenue through the sale of its diagnostic tests to transplant centers and hospitals.
- Pursues strategic partnerships with pharmaceutical companies and healthcare providers.
- Leverages data analytics to develop personalized medicine approaches.
Industry Context
The medical diagnostics industry is experiencing growth driven by technological advancements, an aging population, and increasing demand for personalized medicine. Verici Dx operates within the immuno-diagnostics segment, focusing on the kidney transplantation market. This market is characterized by a need for more accurate and timely diagnostic tools to improve patient outcomes and reduce healthcare costs associated with transplant rejection and graft failure. Competitors include companies like ABDXF (Abbott Diagnostics), ATBPF (Atea Pharmaceuticals), AVEFF (Avacta Group), CNPOF (Cenpos Inc), and LVCLY (LivaNova PLC), some of whom operate in broader diagnostic areas.
Key Customers
- Transplant centers and hospitals that perform kidney transplants.
- Nephrologists and transplant surgeons who manage kidney transplant patients.
- Pharmaceutical companies that develop immunosuppressant drugs.
- Patients who have received or are awaiting kidney transplants.
Financials
Chart & Info
Verici Dx plc (VRCDF) stock price: Price data unavailable
Latest News
No recent news available for VRCDF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRCDF.
Price Targets
Wall Street price target analysis for VRCDF.
MoonshotScore
What does this score mean?
The MoonshotScore rates VRCDF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Sara jane Barrington
CEO
Sara jane Barrington serves as the CEO of Verici Dx plc, leading the company's strategic direction and overseeing its operations. Her background includes extensive experience in the healthcare industry, with a focus on diagnostics and personalized medicine. Prior to joining Verici Dx, she held leadership positions at various biotechnology and pharmaceutical companies, where she was responsible for driving product development, commercialization, and market access. She has a proven track record of building and scaling successful healthcare businesses.
Track Record: Under Sara jane Barrington's leadership, Verici Dx has made significant progress in advancing its pipeline of diagnostic tests for the kidney transplantation market. She has overseen the completion of key clinical trials, secured strategic partnerships, and expanded the company's geographic reach. Her focus on innovation and patient-centric solutions has positioned Verici Dx as a leader in the immuno-diagnostics space.
VRCDF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Verici Dx plc may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier is often associated with higher risk and greater potential for volatility compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher risk of fraud or manipulation.
- Lower liquidity and wider bid-ask spreads.
- Greater price volatility.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's regulatory filings and compliance.
- Monitor the company's trading volume and price volatility.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company is registered with the SEC or other regulatory agencies.
- Company has a professional website and investor relations materials.
- Company has a credible management team and board of directors.
- Company has a clear business model and revenue streams.
- Company is actively communicating with investors and the public.
Verici Dx plc Healthcare Stock: Key Questions Answered
What does Verici Dx plc do?
Verici Dx plc is an immuno-diagnostics company focused on the kidney transplantation market. The company develops and commercializes diagnostic tests designed to improve outcomes for kidney transplant patients. Its in-development product pipeline includes Clarava, a pre-transplant prognosis test; Tuteva, a post-transplant test focused on acute cellular rejection; and Protega, a liquid biopsy test aimed at predicting the risk of fibrosis and long-term graft failure. By providing clinicians with actionable information at critical stages of the transplantation process, Verici Dx aims to improve patient outcomes, reduce healthcare costs, and enhance the overall quality of life for transplant recipients.
What do analysts say about VRCDF stock?
AI analysis is currently pending for VRCDF. Generally, analyst opinions on micro-cap OTC stocks in the diagnostics sector tend to focus on the potential of their technology, the size of their target market, and their ability to secure funding and partnerships. Key valuation metrics would include revenue projections, market penetration rates, and comparisons to similar companies in the diagnostics space. Growth considerations would center on the company's ability to successfully develop and commercialize its diagnostic tests, obtain regulatory approvals, and expand its market reach.
What are the main risks for VRCDF?
As an OTC-listed micro-cap company in the immuno-diagnostics sector, Verici Dx faces several key risks. These include the inherent challenges of developing and commercializing new diagnostic tests, the need to obtain regulatory approvals and secure reimbursement, competition from larger and more established diagnostic companies, and the potential for technological obsolescence. Additionally, the company's small size and limited financial resources make it vulnerable to market fluctuations and economic downturns. Investing in OTC stocks carries additional risks related to liquidity, transparency, and regulatory oversight.
What are the key factors to evaluate for VRCDF?
Verici Dx plc (VRCDF) currently holds an AI score of 61/100, indicating moderate score. Key strength: Focus on the specific niche of kidney transplantation diagnostics. Primary risk to monitor: Competition from larger diagnostic companies. This is not financial advice.
How frequently does VRCDF data refresh on this page?
VRCDF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven VRCDF's recent stock price performance?
Recent price movement in Verici Dx plc (VRCDF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Focus on the specific niche of kidney transplantation diagnostics. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider VRCDF overvalued or undervalued right now?
Determining whether Verici Dx plc (VRCDF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying VRCDF?
Before investing in Verici Dx plc (VRCDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.